Neurological
Refine Search
Pharmaceutical
US drugmaker AbbVie was trading more than 11% lower early on Monday afternoon in New York. 11 November 2024
Pharmaceutical
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research.. 11 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Generics
Over the next decade, the Parkinson's disease (PD) drug market in the leading countries (USA, France, Germany, Italy, Spain, the UK and Japan) will be constrained by generic competition to key therapies, according to a new report from advisory firm Decision Resources. 23 October 2011
Biotechnology
US biotech firm ImmunoGen (Nasdaq: IMGN) says that SAR3419 has started Phase II testing, which triggers a $3 million milestone payment from French drug major Sanofi (Euronext: SAN) as part of a broader collaboration between the companies. 21 October 2011
Generics
Privately-held US drugmaker Prasco Laboratories says it has signed a marketing and distribution agreement with Eli Lilly (NYSE: LLY) to market the authorized generic version of the drug major's blockbuster schizophrenia and bi-polar disorder agent Zyprexa (olanzapine) tablets and Zyprexa Zydis (olanzapine) orally disintegrating tablets, in the US, where it loses patent protection on October 23. 20 October 2011
Pharmaceutical
Laboratoires Servier , France's largest independent drugmaker has entered into a research, development and commercialization deal with USA-based Miragen Therapeutics, a preclinical-stage biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, for three drug candidates, including two of miRagen's lead programs (miR-208 and miR-15/195) and one additional target yet to be identified, for cardiovascular disease. 20 October 2011
Biotechnology
US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new data on their co-marketed multiple sclerosis drug Tysabri (natalizumab) at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS), held in Amsterdam, the Netherlands, showing the benefits of early treatment with the drug. 19 October 2011
Pharmaceutical
The autism spectrum disorder (ASD) therapeutics market was valued at $3.1 billion in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 7.5% over the next eight years to reach $5.5 billion by 2018, finds GlobalData's new report titled Autistic Disorder Therapeutics. 19 October 2011
Pharmaceutical
Within the next 20 years it is expected the number of people with Alzheimer's disease in the UK will double from its current figure of half a million to one million. A new study has looked at whether certain types of drugs used to treat high blood pressure, also called hypertension, might have beneficial effects in reducing the number of new cases of Alzheimer's disease each year. 18 October 2011
Pharmaceutical
US pharma behemoth Pfizer (NYSE: PFE) has commenced executing its commercialization plan for Oxecta (oxycodone HCl, USP) tablets CII in the USA, which was licensed from Acura Pharmaceuticals (Nasdaq: ACUR) by now Pfizer subsidiary King Pharma. 17 October 2011
Pharmaceutical
Shares of US specialty drugmaker Depomed (Nasdaq: DEPO) fell 28.2% to $4.52 last Friday, after the company released top-line results from BREEZE 3, a Phase III trial evaluating the efficacy and safety of Serada (extended-release gabapentin tablets) for menopausal hot flashes, which showed the drug failed to meet one of four study endpoints. 17 October 2011
Biotechnology
Finland-based Biotie Therapies' (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian biotech company Newron Pharmaceuticals (SIX: NWRN) will strengthen its central nervous system (CNS) franchise, adding a strategic partner and a number of assets to its pipeline (The Pharma Letter September 27). 16 October 2011
Pharmaceutical
Following US antitrust clearance last week, Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) has received approval from the European Commission to proceed with its $6.8 billion acquisition of US biotech firm Cephalon (Nasdaq: CEPH), but again with conditions (The Pharma Letter October 10). 14 October 2011
Pharmaceutical
US drug developer Targacept (Nasdaq: TRGT) says it has initiated a potential registration study of AZD3480 in mild-to-moderate Alzheimer's disease, which is being developed under a collaboration with Anglo-Swedish drug major AstraZeneca (LSE: AZN). The study is the subject of a Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration. 12 October 2011
Pharmaceutical
Swiss drug major Roche (ROG: SIX) says that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease. The findings from an early-stage study titled study Mechanism of amyloid removal in patients with Alzheimer disease treated with ganteneruma, were reported in the October issue of Archives in Neurology. 12 October 2011
Pharmaceutical
Results of a study by a group of University of Notre Dame, USA, researchers represent a promising step on the road to developing new drugs for a variety of neurological diseases. The group from the University's Departments of Chemistry and Biochemistry and Biological Sciences and the Friemann Life Sciences Center focused on the design, synthesis and evaluation of water-soluble "gelatinase inhibitor" compounds. 11 October 2011
Generics
The US District of Massachusetts has granted a request by Momenta Pharmaceuticals (Nasdaq: MNTA) and partner Sandoz (the generics unit of Swiss drug major Novartis; NOVN: VX) for a temporary restraining order (TRO) preventing Watson Pharmaceuticals (NYSE: WPI) and Amphastar Pharmaceuticals from marketing or selling Amphastar's enoxaparin sodium injection product, a generic equivalent to French major Sanofi's (Euronext: SAN) Lovenox enoxaparin). 10 October 2011
Pharmaceutical
The Alzheimer's disease drug market will nearly triple over the next 10 years, increasing from $5.4 billion in 2010 to $14.3 billion in 2020 in the developed leading markets of the USA, France, Germany, Italy, Spain, the UK and Japan, notes a new report from advisory firm Decision Resources. The launch of novel agents that affect disease progression will transform the Alzheimer's disease market, which is currently comprised solely of symptomatic therapies. 9 October 2011
Pharmaceutical
In a second drug candidate sale this week, pharma behemoth Pfizer (NYSE: PFE) has agreed to sell rights for the development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, being studied for the treatment of cancer, to fellow USA-based Puma Biotechnology. 7 October 2011
Pharmaceutical
French drug major Sanofi (Euronext: SAN) and its subsidiary Genzyme says that the results of a pivotal Phase III TEMSO study with investigational once-daily oral multiple sclerosis drug Aubagio (teriflunomide), published in The New England Journal of Medicine (NEJM), showed that teriflunomide at the 14mg dosage significantly reduced the annual relapse rate, reduced disability progressions and improved several magnetic resonance imaging (MRI) measures of disease activity, including new or worsening brain lesions. 7 October 2011
Generics
In further patent settlements in the USA, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has now announced agreements with two further companies - Accord Healthcare and its Indian parent company Intas Pharmaceuticals - relating to Accord's proposed generic copy of its blockbuster antipsychotic drug Seroquel XR (quetiapine, extended release). 6 October 2011
Pharmaceutical
The annual cost of brain disorders in Europe has soared to 798 billion euros ($1,070 billion) in what a new study commissioned by the European Brain Council (EBC), describes as a social, political and financial 'ticking bomb.' 5 October 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze